文献速递眼底病与葡萄膜炎

组织型纤溶酶原激活剂或全氟丙烷治疗年龄相关性黄斑变性继发黄斑下出血:析因随机临床试验

Tissue Plasminogen Activator or Perfluoropropane for Submacular Hemorrhage in Age-Related Macular Degeneration: A Factorial Randomized Clinical Trial.
PubMed 文献 · JAMA Ophthalmol · 2024-01-01

这项双盲、假注射对照的析因随机临床试验与可行性研究纳入56例新生血管性年龄相关性黄斑变性继发黄斑下出血患者,随机接受假注射、全氟丙烷(C3F8)、组织型纤溶酶原激活剂(TPA)或C3F8+TPA,并每月按需注射雷珠单抗。析因分析显示,接受TPA的合并组第3个月平均logMAR最佳矫正视力优于未接受TPA组(0.66 vs 0.98,μd=-0.32,95%CI -0.58至-0.07,P=0.02);C3F8组与未接受C3F8组无统计学显著差异。作者认为TPA可能提高视力增益机会,值得考虑进一步临床试验。

要点

  • 接受TPA的合并组第3个月平均logMAR BCVA为0.66,未接受TPA组为0.98,差异有统计学意义(P=0.02)。
  • 接受C3F8组与未接受C3F8组第3个月平均logMAR BCVA无统计学显著差异(0.80 vs 0.90,P=0.43)。
  • 接受TPA的合并组第1个月黄斑下出血存在比例低于未接受TPA组(10/18 vs 21/24,P=0.03)。

核心结论

  • 作者认为,在雷珠单抗治疗新生血管性AMD伴黄斑下出血的眼睛中加用TPA可能提高视力增益机会,值得考虑进一步临床试验。

研究设计与样本

  • 双盲、假注射对照的析因随机临床试验与可行性研究,2014年6月至2019年3月从4个英国玻璃体视网膜单位招募患者,随访12个月。
  • 纳入标准为继发于新生血管性AMD、累及中心凹且面积至少1个视盘面积的黄斑下出血,并在发病14天内评估。
  • 研究眼接受基线雷珠单抗后按2:1:1:1随机分配至假注射(n=23)、C3F8(n=11)、TPA(n=11)或C3F8+TPA(n=11)玻璃体腔注射。
  • 所有眼接受每月按需雷珠单抗治疗12个月,结果评估者对干预分配设盲。

主要发现

  • 56例参与者中53例(95%)达到主要终点;平均(SD)年龄81.5(8.1)岁,女性33例(59%)。
  • 析因分析显示,接受TPA的合并组第3个月平均logMAR BCVA为0.66,未接受TPA组为0.98(μd=-0.32;95%CI -0.58至-0.07;P=0.02)。
  • 接受C3F8组与未接受C3F8组第3个月平均logMAR BCVA分别为0.80和0.90(μd=-0.11;95%CI -0.37至0.16;P=0.43),无统计学显著差异。
  • 接受TPA的合并组第1个月黄斑下出血存在比例为10/18(55.6%),未接受TPA组为21/24(87.5%)(P=0.03),该获益在C3F8合并组中未显现。
  • 第3个月平均logMAR BCVA在各组间无统计学显著差异:单药对照组0.99;C3F8组0.97(vs 对照 μd=-0.02;95%CI -0.48至0.44);TPA组0.70(vs 对照 μd=-0.29;95%CI -0.79至0.21);C3F8+TPA组0.71(vs 对照 μd=-0.36;95%CI -0.82至0.11);P=0.11。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者在结论中提出值得考虑进一步临床试验(warranting consideration of additional clinical trials)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Evidence is limited to support therapies to treat submacular hemorrhage (SMH) secondary to neovascular age-related macular degeneration (AMD) as an adjunct to anti-vascular endothelial growth factor therapy (anti-VEGF). OBJECTIVE: To determine if intravitreal tissue plasminogen activator (TPA) or gas improves visual acuity or promotes resolution of SMH secondary to neovascular AMD in eyes treated with ranibizumab. DESIGN, SETTING, AND PARTICIPANTS: This was a double-masked, sham-controlled, factorial randomized clinical trial and feasibility study that recruited participants from June 2014 to March 2019, with 12 months' follow-up. Included in the trial were patients from 4 UK vitreoretinal units who had fovea-involving SMH of at least 1 disc area secondary to neovascular AMD and were evaluated within 14 days of onset. INTERVENTIONS: Study eyes received baseline ranibizumab and were then randomized 2:1:1:1 to 1 of 4 intravitreal treatments: sham injection, perfluoropropane (C3F8), TPA, or combined C3F8 and TPA (C3F8 + TPA). All eyes received monthly pro re nata ranibizumab therapy over 12 months. Outcome assessors were masked to intervention assignment. MAIN OUTCOME AND MEASURE: Best-corrected visual acuity (BCVA) at month 3. RESULTS: Fifty-three of 56 participants (95%; mean [SD] age, 81.5 [8.1] years; 33 female [59%]) reached the primary end point. Study eyes were randomized to the following intravitreal treatments: sham injection (n = 23), C3F8 (n = 11), TPA (n = 11), or C3F8 + TPA (n = 11). On factorial analysis, the combined TPA groups had significantly better month 3 mean logMAR BCVA than those not receiving TPA: 0.66 vs 0.98 (μd = -0.32; 95% CI, -0.58 to -0.07; P = .02). There was no statistically significant difference comparing groups that did vs did not receive C3F8: 0.80 vs 0.90 (μd = -0.11; 95% CI, -0.37 to 0.16; P = .43). The combined TPA groups were less likely to have SMH present at month 1 (10 of 18 [55.6%] vs 21 of 24 [87.5%]; P = .03), a benefit not evident in the combined gas groups. The mean logMAR BCVA at 3 months was not significantly different between the groups: monotherapy control, 0.99; C3F8, 0.97 (vs control μd = -0.02; 95% CI, -0.48 to 0.44); TPA, 0.70 (vs control μd = -0.29; 95% CI, -0.79 to 0.21); combined C3F8 and TPA, 0.71 (vs control μd = -0.36; 95% CI, -0.82 to 0.11); P = .11. No safety differences were identified across the treatment groups. CONCLUSIONS AND RELEVANCE: Results of this randomized clinical trial suggest that TPA may increase the chance of visual acuity gain when added to ranibizumab therapy for neovascular AMD in eyes with SMH, warranting consideration of additional clinical trials. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01835067.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Murphy GSP, Saleh A, Ayis S, et al. Tissue Plasminogen Activator or Perfluoropropane for Submacular Hemorrhage in Age-Related Macular Degeneration: A Factorial Randomized Clinical Trial. JAMA Ophthalmol. 2024. PMID: 39418015. doi:10.1001/jamaophthalmol.2024.4297

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。